Please assess the completion status of the following clinical trial:

Trial Title: Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females, ≥ 18 years of age~* Diagnosis of chronic, moderate to severe plaque psoriasis for at least 12 months prior to Screening, and a candidate for phototherapy and/or systemic (including etanercept) therapy~* Had an inadequate response, intolerance, or contraindication to at least 1 conventional systemic agent for the treatment of psoriasis.~* No prior exposure to biologics for treatment of psoriatic arthritis or psoriasis~Exclusion Criteria:~* Other than psoriasis, history of any clinically significant and uncontrolled systemic diseases; any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study.~* Pregnant or breast feeding.~* Have failed more than 3 systemic agents for treatment of psoriasis.~* History of allergy to any component of the investigational product (IP), including human immunoglobulin (Ig) proteins or allergy to etanercept.~* Hepatitis B surface antigen or anti-hepatitis C antibody positive at Screening.~* Latent, active tuberculosis (TB) or inadequately treated TB; nontuberculous mycobacterial infection or opportunistic infection (eg, cytomegalovirus, Pneumocystis carinii, aspergillosis, Clostridium difficile).~* Have a history of, or ongoing, chronic or recurrent infectious disease~* Have received, or are expected to receive, any live virus or bacterial vaccination within 3 months before first administration of IP, or through Week 20 during the study.~* Had a Bacillus Calmette-Guérin (BCG) vaccination within 1 year prior to screening.~* History of positive human immunodeficiency virus (HIV), or have congenital or acquired immunodeficiency (eg, common variable immunodeficiency disease).~* Active substance abuse or a history of substance abuse within 6 months prior to Screening.~* Malignancy or history of malignancy, except for treated \[ie, cured\] basal cell or squamous cell in situ skin carcinomas and cervical intraepithelial neoplasia \[CIN\] or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years.~* Psoriasis flare or rebound within 4 weeks prior to Screening.~* Topical therapy within 2 weeks of randomization or systemic therapy for psoriasis within 4 weeks prior to randomization~* Use of phototherapy within 4 weeks prior to randomization or prolonged sun exposure or use of tanning booths or other ultraviolet (UV) light sources.~* Any investigational drug within 4 weeks prior to randomization, or 5 pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer).~* Prior treatment with apremilast or etanercept.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apremilast 30 mg plus placebo injection (Type: EXPERIMENTAL): Apremilast 30 mg tablets orally twice a day (BID) plus once weekly (QW) evaluator/subject-blinded subcutaneous (SC) saline (placebo) injections
- Etanercept 50 mg plus placebo tablet (Type: EXPERIMENTAL): Etanercept 50 mg evaluator/subject-blinded SC QW injections plus placebo tablets orally BID
- Oral placebo tablets plus SC placebo injections (Type: PLACEBO_COMPARATOR): Identically matching placebo tablets and evaluator/subject-blinded SC injections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete